Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool.

Autor:	Pinto-Carbó M; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain., Vanaclocha-Espí M; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain., Martín-Pozuelo J; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain., Romeo-Cervera P; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain., Hernández-García M; Environmental Health Service, Utiel Public Health Centre, Ministry of Universal and Public Health, Utiel, Valencia Region, Spain., Ibáñez J; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain.; Healthcare Integration Service, Directorate General for Health Care, Regional Ministry of Health, Valencia, Spain., Castán-Cameo S; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain.; Screening Programs Service, General Directorate of Public Health, Regional Ministry of Health, Valencia, Spain., Salas D; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain., van Ravesteyn NT; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., de Koning H; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Zurriaga Ó; Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Legal Medicine, University of Valencia, Valencia, Spain.; Joint Research Unit on Rare Diseases, FISABIO-University of Valencia (FISABIO-UVEG), Valencia, Spain., Molina-Barceló A; Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO-Public Health), Valencia, Spain.
Jazyk:	angličtina
Zdroj:	European journal of public health [Eur J Public Health] 2024 Aug 01; Vol. 34 (4), pp. 806-811.
DOI:	10.1093/eurpub/ckae068
Abstrakt:	Background: The recommendation for the implementation of mammography screening in women aged 45-49 and 70-74 is conditional with moderate certainty of the evidence. The aim of this study is to simulate the long-term outcomes (2020-50) of using different age range scenarios in the breast cancer screening programme of the Valencia Region (Spain), considering different programme participation rates. Methods: Three age range scenarios (S) were simulated with the EU-TOPIA tool, considering a biennial screening interval: S1, 45-69 years old (y); S2, 50-69 y and S3, 45-74 y. Simulations were performed for four participation rates: A = current participation (72.7%), B = +5%, C = +10% and D = +20%. Considered benefits: number (N°) of in situ and invasive breast cancers (BC) (screen vs. clinically detected), N° of BC deaths and % BC mortality reduction. Considered harms: N° of false positives (FP) and % overdiagnosis. Results: The results showed that BC mortality decreased in all scenarios, being higher in S3A (32.2%) than S1A (30.6%) and S2A (27.9%). Harms decreased in S2A vs. S1A (N° FP: 236 vs. 423, overdiagnosis: 4.9% vs. 5.0%) but also benefits (BC mortality reduction: 27.9% vs. 30.6%, N° screen-detected invasive BC 15/28 vs. 18/25). In S3A vs. S1A, an increase in benefits was observed (BC mortality reduction: 32.2% vs. 30.6%), N° screen-detected in situ B: 5/2 vs. 4/3), but also in harms (N° FP: 460 vs. 423, overdiagnosis: 5.8% vs. 5.0%). Similar trends were observed with increased participation. Conclusions: As the age range increases, so does not only the reduction in BC mortality, but also the probability of FP and overdiagnosis. (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Public Health Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu